Physician profile
Alfred D Johnson
NPI 1396900510
$2,835.55
in general payments reported to CMS, 2019-2025
34 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $97.45 · 2021: $150 · 2022: $250 · 2023: $447 · 2024: $789 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.13 | 2021-2025 | |
| Pfizer INC. | $522.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $293.38 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Amgen INC. | $157.67 | 2019-2024 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $147.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $142.33 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $119.25 | 2019-2024 | Reyvow, Emgality, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $105.79 | 2019-2025 | Trintellix |
| Edwards Lifesciences Corporation | $82.66 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Teva Pharmaceuticals USA, INC. | $54.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $49.77 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $43.42 | 2020-2025 | Breztri |
| Supernus Pharmaceuticals, INC. | $43.31 | 2021-2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $42.18 | 2025 | Jornay Pm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $33.88 | 2023 | |
| Novartis Pharmaceuticals Corporation | $33.60 | 2019-2023 | |
| Allergan, INC. | $31.47 | 2019 | |
| Phathom Pharmaceuticals, INC. | $26.61 | 2024-2025 | Voquezna |
| Beigene USA, INC. | $23.60 | 2023 | Brukinsa |
| Vertex Pharmaceuticals Incorporated | $20.44 | 2024 | |
| Merck Sharp & Dohme LLC | $20.19 | 2025 | Vaxneuvance, Enflonsia |
| Abbott Laboratories | $18.78 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.80 | 2024 | Ycanth |
| Axsome Therapeutics, INC. | $17.24 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $16.45 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $15.78 | 2023 | Abilify Maintena, Rexulti |
| Kowa Pharmaceuticals America, INC. | $14.41 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $14.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.63 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $12.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.46 | 2019 | |
| Seqirus USA INC | $12.41 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.